ArticleOncotarget2017
Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Pooled it
- An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.Bioscience reports · 2020Pooled it
- Targeting the FGF19/FGFR4 positive feedback loop to disrupt ERK-mediated tumor progression in head and neck cancer.Journal of translational medicine · 2026Article
- Structural pharmacogenomics of drug-associated SNPs in oral squamous cell carcinoma.Frontiers in genetics · 2026Article
- FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM patients: findings of a pilot study.Frontiers in medicine · 2025Article
- Association of the rs1966265 and rs351855Biomedicines · 2024Article
- Potential impact of ADAM-10 genetic variants with the clinical features of oral squamous cell carcinoma.Journal of cellular and molecular medicine · 2023Article
- Proteogenomic links to human metabolic diseases.Nature metabolism · 2023Article
- Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.Scientific reports · 2021Article
- Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer.Frontiers in pharmacology · 2021Review
- Genetic alterations and clinical dimensions of oral cancer: a review.Molecular biology reports · 2020Review
- FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.Cancer research and treatment · 2020Article
- FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan.International journal of environmental research and public health · 2020Article
- Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma.International journal of environmental research and public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrations of the fibroblast growth factor receptor 4 (FGFR4) genomic region include amplification of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.